Newsstand | Page 16 | Aplastic Anemia and MDS International Foundation

Newsstand

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

Serving Breakfast to ‘Champions’ at Nurses Symposium

Originally Published: 05/12/2016
Nurses have always been the unsung heroes, as well as the backbone, of the health care system. With thousands of them gathered in San Antonio, Texas, last month for the 41st Oncology Nursing Society Congress, AAMDSIF hosted a Breakfast Symposium to kick off their first day of this annual meeting. Over 300 oncology nurses attended our presentation – hungry for the scientific news, as well as a hearty meal to start their long day of sessions. Accustomed to early calls and long hours, the nurses began arriving around 5am. Our presentation panel included Nancy Corbitt, Joan Latsko and Barbara...

WHO Criteria and Diagnosis in MDS

Originally Published: 05/12/2016
On May 12, OncLive’s online series Peer Exchange featured AAMDSIF Medical Advisory Board member, Mikkael A. Sekeres, MD, MS, of the Cleveland Clinic Taussig Cancer Institute, in a discussion on MDS.

NHLBI profiles a member of the Foundation’s patient community.

Originally Published: 05/11/2016
Emily Berry Hoak lives one active life. A former professional tour guide for Colonial Williamsburg, with nearly 30 years of service to her credit, she is used to being on her feet for hours at a time. Daily 1- to 2-mile walks and frequent trips to the pool for 40-minute swims are just part of her regular routine, as are lively and cherished outings with family and friends. One day in 2012, however, something tried to put the brakes on Emily’s busy lifestyle: aplastic anemia, a form of bone marrow failure. This rare disorder prevents the bone marrow — the spongy tissue inside the bones — from...

Health Professionals Update - Spring 2016

Originally Published: 04/30/2016
Shared Decision-Making and Communication Strategies for MDS Patients For nurses and nurse practitioners in hematology/oncology, oncology or primary care settings, this new module provides a comprehensive review of shared decision making and communication strategies to improve treatment goals for patients with myelodysplastic syndromes including: Shared decision making Patient-centered communication Clinical decision support Communication skills for health care providers Learn more about AAMDSIF Nursing Modules.

Foundation Update - April 2016

Originally Published: 04/15/2016
Foundation Update Newsletter - April 2016   2016 AAMDSIF Scientific Symposium: Experts Debate and Discuss the State of Research and Treatment “This symposium was the best one yet – we’re lucky to have these wonderful presentations and discussions, and to leave with lots of ideas and possibilities for new work and collaboration.”  -- Neal Young, MD, National Heart, Lung and Blood Institute, National Institutes of Health On March 17-18, over 100 leading researchers and clinicians attended the 5th International Bone Marrow Failure...

Aplastic Anemia Research Summary from ASH 2015

Originally Published: 01/01/2016
A summary of selected scientific abstracts from the 2015 American Society of Hematology Annual Meeting. Read the abstracts for aplastic anemia.

MDS Research Summary from ASH 2015

Originally Published: 01/01/2016
A summary of selected scientific abstracts from the 2015 American Society of Hematology Annual Meeting. Read the abstracts for MDS.

PNH Research Summary from ASH 2015

Originally Published: 01/01/2016
A summary of selected scientific abstracts from the 2015 American Society of Hematology Annual Meeting. Read the abstracts for PNH.

Advances in the molecular pathology of MDS

Originally Published: 11/19/2015
Stephanie Halene, M.D. Assistant Professor Section of Hematology/Department of Internal Medicine and Yale Cancer Center And Kai Rejeski, Visiting Medical Student, Freiburg University Yale University School of Medicine Molecular pathology of myelodysplastic syndromes: new developments and implications for diagnosis and treatment. Zhang X, Lancet JE, Zhang L. Leuk Lymphoma. 2015 May 26:1-9. [Epub ahead of print] Current and novel therapeutic approaches in myelodysplastic syndromes. Estephan F, Tiu RV. J Community Support Oncol. 2014 Jul;12(7):236-249. doi: 10.12788/jcso.0057. Review. PMID...

Options for MDS patients beyond HMAs

Originally Published: 11/19/2015
Stephanie Halene, M.D. Assistant Professor Section of Hematology/Department of Internal Medicine and Yale Cancer Center And Edo Kapetanovic, Visiting Medical Student, University of Rijeka, Croatia Yale University School of Medicine In this article, Roberts and Steensma explore the critical question of what to do for those patients with myelodysplasia (MDS) who fail hypomethylating agents (HMAs) either upfront or after a period of response. HMAs, azacytidine and decitabine, were approved for International Prognostic Scoring System (IPSS) intermediate-2 and high-risk MDS in 2004 and 2006,...